Characterisation of oncology EHR-derived real-world data in the UK, Germany, and Japan
Oncology real-world data (RWD) from electronic health records (EHRs) can generate real-world evidence crucial for clinical and policy decisions. However, challenges in accessing and harmonising data across countries limit its global applicability. Flatiron Health has developed oncology EHR-derived RWD datasets in the UK, Germany, and Japan, integrating these with its United States database to support multinational studies. This paper outlines the methods, aligned with the ISPOR EHR-derived data SUITABILITY checklist, to ensure the trustworthiness, reliability, and relevance of these datasets.
Authors
- Harlan Pittell (ORCID: https://orcid.org/0000-0001-9969-4927)
- Philani Mpofu (ORCID: https://orcid.org/0000-0002-6474-029X)
- Afshin Samani (ORCID: https://orcid.org/0000-0001-6119-8231)
- Elsie Horne (ORCID: https://orcid.org/0000-0002-5545-7628)
- Kathi Seidl-Rathkopf
- Arunan Sujenthiran (ORCID: https://orcid.org/0000-0003-1304-3942)
- Eri Tajima (ORCID: https://orcid.org/0009-0002-2051-1548)
- Qiang Zhang (ORCID: https://orcid.org/0000-0002-8659-5396)
- Blythe J. S. Adamson (ORCID: https://orcid.org/0000-0003-4251-2912)
- Nicole Schinwald
- Christoph Buhl
- D. Ng (ORCID: https://orcid.org/0009-0009-2692-9436)
- Chongyang Xu
Institutions
- Flatiron Health (United States) (US)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100113
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Flatiron Health